HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TIL...
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease an...
Aleix Prat is leading the research, which focuses on discovering new ways of diagnosing hormone receptor-positive breast cancer, as well as new the...
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organizati...
Researchers from Hospital Clínic-IDIBAPS have shown for the first time that the benefit of chemotherapy in premenopausal patients with low-risk hor...
In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity...
Reveal Genomics’ first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.
Today the results of the phase 2 CORALLEEN clinical trial, promoted by the international academic group SOLTI, have been presented. The study, publ...
